CGI560

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406100

CAS#: 845269-74-1

Description: CGI560 is a potent BTK inhibitor with IC50 = 400 nM for BTK.


Price and Availability

Size
Price

Size
Price

Size
Price

CGI560 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406100
Name: CGI560
CAS#: 845269-74-1
Chemical Formula: C29H27N5O
Exact Mass: 461.22156
Molecular Weight: 461.55758
Elemental Analysis: C, 75.46; H, 5.90; N, 15.17; O, 3.47


Synonym: CGI560; CGI560; CGI 560

IUPAC/Chemical Name: 4-(tert-butyl)-N-(3-(8-(phenylamino)imidazo[1,2-a]pyrazin-6-yl)phenyl)benzamide

InChi Key: IJMHHZDBRUGXNO-UHFFFAOYSA-N

InChi Code: InChI=1S/C29H27N5O/c1-29(2,3)22-14-12-20(13-15-22)28(35)32-24-11-7-8-21(18-24)25-19-34-17-16-30-27(34)26(33-25)31-23-9-5-4-6-10-23/h4-19H,1-3H3,(H,31,33)(H,32,35)

SMILES Code: O=C(NC1=CC=CC(C2=CN3C(C(NC4=CC=CC=C4)=N2)=NC=C3)=C1)C5=CC=C(C(C)(C)C)C=C5


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1: Lou Y, Owens TD, Kuglstatter A, Kondru RK, Goldstein DM. Bruton's tyrosine kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies. J Med Chem. 2012 May 24;55(10):4539-50. doi: 10.1021/jm300035p. Epub 2012 Mar 21. Review. PubMed PMID: 22394077.